NYSEAMERICAN:NBY

NovaBay Pharmaceuticals (NBY) Stock Price, News & Analysis

$0.08
+0.01 (+9.35%)
(As of 10:39 AM ET)
Today's Range
$0.08
$0.09
50-Day Range
N/A
52-Week Range
$0.07
$1.42
Volume
817,840 shs
Average Volume
3.33 million shs
Market Capitalization
$354,482.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
NBY stock logo

About NovaBay Pharmaceuticals Stock (NYSEAMERICAN:NBY)

NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

NBY Stock Price History

NBY Stock News Headlines

These AI trades triggered this morning (545% return)
If you think a market crash is possible in 2024, I don't know why you're not using this yet.
Q4 2023 NovaBay Pharmaceuticals Inc Earnings Call
NovaBay Pharmaceuticals Inc.
These AI trades triggered this morning (545% return)
If you think a market crash is possible in 2024, I don't know why you're not using this yet.
NovaBay Pharmaceuticals, Inc. (NBY)
Recap: NovaBay Pharmaceuticals Q3 Earnings
NovaBay Pharmaceuticals: CEO Interview
Why NovaBay Pharmaceuticals Stock Is Blasting Higher
See More Headlines
Receive NBY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NovaBay Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/26/2024
Today
4/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NYSEAMERICAN:NBY
Employees
24
Year Founded
N/A

Profitability

Net Income
$-10,610,000.00
Pretax Margin
-79.70%

Debt

Sales & Book Value

Annual Sales
$14.40 million
Book Value
$1.53 per share

Miscellaneous

Free Float
4,160,000
Market Cap
$324,170.00
Optionable
Not Optionable
Beta
2.82
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Justin M. Hall Esq. (Age 46)
    President, CEO, General Counsel, Chief Compliance Officer, Corporate Secretary & Director
    Comp: $364.15k
  • Mr. Tommy Law (Age 39)
    Controller, Interim CFO & Treasurer
    Comp: $155.48k

NBY Stock Analysis - Frequently Asked Questions

How have NBY shares performed in 2024?

NovaBay Pharmaceuticals' stock was trading at $0.1802 at the beginning of the year. Since then, NBY stock has decreased by 53.3% and is now trading at $0.0842.
View the best growth stocks for 2024 here
.

Are investors shorting NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals saw a decrease in short interest during the month of April. As of April 15th, there was short interest totaling 208,100 shares, a decrease of 71.0% from the March 31st total of 718,800 shares. Based on an average trading volume of 3,490,000 shares, the short-interest ratio is presently 0.1 days. Approximately 0.6% of the shares of the company are sold short.
View NovaBay Pharmaceuticals' Short Interest
.

How were NovaBay Pharmaceuticals' earnings last quarter?

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) announced its earnings results on Tuesday, March, 26th. The biopharmaceutical company reported ($0.95) earnings per share for the quarter. The biopharmaceutical company had revenue of $3.73 million for the quarter. NovaBay Pharmaceuticals had a negative net margin of 79.70% and a negative trailing twelve-month return on equity of 146.20%.

When did NovaBay Pharmaceuticals' stock split?

Shares of NovaBay Pharmaceuticals reverse split on the morning of Wednesday, November 16th 2022. The 1-35 reverse split was announced on Wednesday, November 16th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 16th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of NovaBay Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NovaBay Pharmaceuticals investors own include Aeterna Zentaris (AEZS), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Bionano Genomics (BNGO), Heat Biologics (HTBX), iBio (IBIO), Matinas BioPharma (MTNB), Novan (NOVN), ADMA Biologics (ADMA) and Vaxart (VXRT).

How do I buy shares of NovaBay Pharmaceuticals?

Shares of NBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:NBY) was last updated on 4/26/2024 by MarketBeat.com Staff

From Our Partners